U.S. Firm Pearl Acquired by AstraZeneca

AstraZeneca has agreed to buy Pearl Therapeutics a respiratory specialist firm in the U.S., for $1.15 billion. The second largest drug maker in Britain is attempting to rebuild it pipeline for products through acquisitions.

The new acquisition of the private company secures a position for AstraZeneca in the new emerging market of a new class of treatments for lungs know by the terms LABA/LAMA that is promising to improve disease control and patient compliance, without the use of steroids.

Some analysts in the industry believe that the new LABA/LAMA inhalers are ready to dominate the future therapy for COPD or chronic obstructive pulmonary disease, which causes a debilitating breathlessness affecting close to 210 million people around the world.

By purchasing Pearl, based in Redwood City, California, AstraZeneca is able to fill a gap in its respiratory portfolio. Nevertheless, it will remain behind rivals Novartis and GlaxoSmithKline in a race to develop the new form of inhaled medication.

The Britain drug maker announced Monday it would be paying $560 million initially plus up to another $450 million if development milestone are reached, as well as payments that are sale-related of as much as $140 million more.

This latest transaction is important for Pascal Soriot, the new CEO of the company, who took the reins last October.

Sales and profits at AstraZeneca have fallen as its older medicines began to lose protection from patents and new products are badly needed by the company to replaces big sellers it previously had such as Seroquel, which is no longer protected by patent.



Latest News

Insider Selling: Diamondback Energy Inc  VP Sells $536,400.00 in Stock
Insider Selling: Diamondback Energy Inc VP Sells $536,400.00 in Stock
Insider Selling: Gran Colombia Gold Corp  Senior Officer Sells C$836,403.50 in Stock
Insider Selling: Gran Colombia Gold Corp Senior Officer Sells C$836,403.50 in Stock
Low & Bonar  Rating Reiterated by Peel Hunt
Low & Bonar Rating Reiterated by Peel Hunt
BidaskClub Lowers Automatic Data Processing  to Hold
BidaskClub Lowers Automatic Data Processing to Hold
Head-To-Head Analysis: ENDRA Life Sciences  & Its Competitors
Head-To-Head Analysis: ENDRA Life Sciences & Its Competitors
Autodesk  versus Textmunication Holdgings  Critical Comparison
Autodesk versus Textmunication Holdgings Critical Comparison


 
© 2006-2019 Zolmax.